Drug
Vqw 765
Vqw 765: highest development phase Phase 3, developed by Vanda Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Vanda Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| VQW-765 NCT07221578 | Phase 3 | Social Anxiety Disorder (SAD) |
Latest
No recent events.
Follow Vqw 765 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.